Insulin counter-regulatory factors, fibrinogen and C-reactive protein during olanzapine administration: Effects of the antidiabetic metformin

International Clinical Psychopharmacology

Volumn 22, Issue 2, 2007, Pages 69-76

  Baptista, Trino ^a,f   Sandia, Ignacio ^a   Lacruz, Anny ^a   Rangel, Nairy ^b   Mendoza, Soaira De ^c   Beaulieu, Serge ^d   Contreras, Quilianio ^e   Galeazzi, Tatiana ^a   Vargas, Doritza ^a  

^a Universidad De Los Andes Facultad de Medicina   (Venezuela)

^b Psychiatric Institute 'Dr Raúl Castillo'   (Venezuela)

^c Metabolism Center   (Venezuela)

^d MCGILL UNIVERSITY   (Canada)

^e Experimental University of Santa Bárbara   (Venezuela)

^f NONE   (Venezuela)

Author keywords

Atypical antipsychotics; Insulin resistance; Metformin; Procoagulant states; Proinflamatory

Indexed keywords

C REACTIVE PROTEIN; FIBRINOGEN; GLUCAGON; GROWTH HORMONE; HYDROCORTISONE; INSULIN; LEPTIN; METFORMIN; OLANZAPINE; PLACEBO; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; INSULIN RESISTANCE; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; WEIGHT GAIN;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BLOOD GLUCOSE; C-REACTIVE PROTEIN; DOUBLE-BLIND METHOD; FEMALE; FIBRINOGEN; GLUCAGON; HUMAN GROWTH HORMONE; HUMANS; HYDROCORTISONE; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; LEPTIN; MALE; METABOLIC SYNDROME X; METFORMIN; MIDDLE AGED; SCHIZOPHRENIA; SEX FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33846957689     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/YIC.0b013e32801182e6     Document Type: Article

References (49)

1. American Psychiatric Association (1994). Diagnostic and statistical manual of mental disorders. 4th ed. Washington, District of Columbia: American Psychiatric Association.
2. Ardizzone TD, Bradley RJ, Freeman AM, Dwyer DS (2001). Inhibition of glucose transport in PC12 cells by the atypical antipsychotic drugs risperidone and clozapine and structural analogs of clozapine. Brain Res 923:82-90.
3. Baptista T, Mendoza S, Beaulieu S, Martinez M, Bermúdez A (2004a). The metabolic syndrome during antipsychotic drug treatment: mechanisms and management. Metab Synd Relat Disord 2:190-207.
4. Baptista T, Martinez M, Lacruz A, Mendoza S, Hernández L (2004b). Insulin sensitivity and anti-insulin factors during olanzapine or risperidone administration in patients with chronic mental disorders. Society for Neuroscience 36th Annual Meet San Diego, California; Abstract 893.12.
5. Baptista T, Martinez J, Lacruz A, Rangel N, Serrano A, Arapé Y, et al. (2006). Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind, placebo-controlled trial. Can J Psychiatry 51:192-196.
6. Birkas Kovats D, Palik E, Faludi G, Cseh K (2005). Possible connection between ghrelin, resistin and TNF-alpha levels and the metabolic syndrome caused by atypical antipsychotics. Neuropsychopharmacology Hungary 7:132-139.
7. Chan JL, Blüher S, Yiannakouris N, Suchard MA, Kratzsch J, Mantzoros CS (2002). Regulation of circulating soluble leptin receptor levels by gender, adiposity, sex steroids, and leptin: observational and interventional studies in humans. Diabetes 51:2105-2112.
8. Cohrs S, Roher C, Jordan W, Meier A, Huether G, Wuttke W, et al. (2006). The atypical antipsychotics olanzapine and quetiapine, but not haloperidol, reduce ACTH and cortisol secretion in healthy subjects. Psychopharmacology (Berlin) 185:11-18.
9. Dwyer DS, Donohoe D (2003). Induction of hyperglycemia in mice with atypical antipsychotic drugs that inhibits glucose uptake. Pharmacol Biochem Behav 75:255-260.
10. Dwyer DS, Donohoe D, Lu XH, Aamodi EJ (2005). Mechanistic connections between glucose/lipid disturbances and weight gain induced by antipsychotic drugs. Int Rev Neurobiol 65:211-247.
11. Ebenbichler C, Laimer M, Kranebitter M, Lechleitmer M, Patsch JR, Baumgartner S, et al. (2005). The soluble leptin receptor in olanzapine-induced weight gain: results from a prospective study. Schizophr Res 75:143-146.
12. Engl J, Laimer M, Niederwanger A, Kranebitter M, Starzinger M, Pedrini M-T, et al. (2005). Olanzapine impairs glycogen synthesis and insulin signaling in L6 skeletal muscle cells. Mol Psychiatry 10:1089-1096.
13. Festa A, D'Agostino R Jr, Mykkanen L, Tracy RP, Zaccaro DJ, Hales CN, et al. (1999). Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance: the Insulin Resistance Atherosclerosis Study (IRAS). Arterioscler Thromb Vasc Biol 19:562-568.
14. Festa A, D'Agostino R Jr, Howard G, Mykkanen L, Tracy RP, Haffner SM (2000). Chronic subclinical inflammation as part of the insulin resistance syndrome. Circulation 102:42-47.
15. Festa A, D'Agostino R Jr, Tracy RP, Haffner SM (2002). Elevated levels of acute phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the Insulin Resistance Atherosclerosis Study. Diabetes 51:1131-1137.
16. Fonseca V, Jawa A (2005). Endothelial and erectile dysfunction, diabetes mellitus, and the metabolic syndrome: common pathways and treatments? Am J Cardiol 92:13M-18M.
17. Fruehwald-Schultes B, Oltmanns KM, Toschek B, Sopke S, Kern W, Born J, et al. (2002). Short-term treatment with metformin decreases serum leptin concentration without affecting body weight and body fat content in normal-weight healthy men. Metabolism 51:531-536.
18. Grieninger G, Plant PW, Liang TJ, Kalb RG, Amrani D, Mosesson MV, et al. (1983). Hormonal regulation of fibrinogen synthesis in cultured hepatocytes. Ann N Y Acad Sci 408:469-499.
19. Haffner SM (2006). The metabolic syndrome: inflammation, diabetes mellitus and cardiovascular diseases. Am J Cardiol 97:3A-11A.
20. Haffner S, Temprosa M, Crandall J, Fowler S, Goldberg R, Horton E, et al. (2005). Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes 54:1566-1572.
21. Hagg S, Spigset O (2002). Antipsychotic-induced venous thromboembolism: a review of the evidence. Cent Nerv Syst Drugs 16:765-676.
22. Harris RBS (2000). Leptin: much more than a satiety signal. Annu Rev Nutr 20:45-75.
23. Kamohara S, Burcelin R, Halaas JL, Friedman JM, Charron MJ (1997). Acute stimulation of glucose metabolism in mice by leptin treatment. Nature 389:374-377.
24. Kim JY, Park YH, Park SY, Won KC, Choi KH, Huh JY, et al. (2006). Metformin restores leptin sensitivity in high-fat-fed obese rats with leptin resistance. Diabetes 55:716-724.
25. Klein J, Westphal S, Kraus D, Meier B, Perwitz N, Ott V, et al. (2004). Metformin inhibits leptin secretion via a mitogen-activated protein kinase signalling pathway in brown adipocytes. J Endocrinol 183:299-307.
26. Li L, Mamputu JC, Wiernsperger N, Renier G (2005). Signaling pathways involved in human vascular smooth muscle cell proliferation and matrix metalloproteinase-2 expression induced by leptin: inhibitory effect of metformin. Diabetes 54:2227-2234.
27. Liperoti R, Pedone C, Lapane KL, Mor V, Bernabei R, Gambassi G (2005). Venous thromboembolism among elderly patients treated with atypical and conventional antipsychotic agents. Arch Intern Med 165:2677-2682.
28. Mann K, Rossbach W, Muller MJ, Muller-Siecheneder F, Pott T, Linde I (2006). Nocturnal hormone profiles in patients with schizophrenia treated with olanzapine. Psychoneuroendocrinology 31:256-264.
29. Mannucci E, Tesi F, Bardini G, Ognibene A, Petracca MG, Ciani S (2004). Effects of metformin on glucagon-like peptide-1 levels in obese patients with and without type 2 diabetes. Diabetes Nutr Metab 17:336-342.
30. Markianos M, Hatzimanolis J, Lykouras L (1999). Switch from neuroleptics to clozapine does not influence pituitary-gonadal axis hormone levels in male schizophrenic patients. Eur Neuropsychopharmacol 9:533-536.
31. Melkersson KI, Hulting AL, Brismar KE (2000). Elevated levels of insulin, leptin and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. J Clin Psychiatry 6:742-749.
32. Mlinar B, Marc J, Janez A, Pfeifer M (2007). Molecular mechanisms of insulin resistance and associated diseases. Clin Chim Acta 375: 20-35 (Epub 2006 July 14).
33. Morin-Papunen IC, Koivunen RM, Tomas C, Ruokonen A, Martikainen HK (1998). Decreased serum leptin concentrations during metformin therapy in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 83:2566-2568.
34. Mueller WM, Stanhope KL, Gregoire F, Evans JL, Havel PJ (2000). Effects of metformin and vanadium on leptin secretion from cultured rat adipocytes. Obes Res 8:530-539.
35. Neumann AC, Jordan W, Huether G, Rodenbeck A, Ruther G (2005). Ziprasidone decreases cortisol excretion in healthy subjects. J Clin Pharmacol 60:330-336.
36. Ozata M, Oktenli C, Bingol N, Ozdemir IC (2001). The effects of metformin and diet on plasma testosterone and leptin levels in obese men. Obes Res 9:662-667.
37. Pacini G, Mari A (2003). Methods for clinical assessment of insulin sensitivity and β-cell function. Best Pract Res Clin Endocrinol Metab 17:305-322.
38. Reaven GM (2005). Insulin resistance, the insulin resistance syndrome, and cardiovascular disease. Panminerva Med 47:201-210.
39. Ryan MC, Flanagan S, Kinsella U, Keeling F, Thakore JH (2004). The effects of atypical antipsychotics on visceral fat distribution in first episode, drug-naive patients with schizophrenia. Life Sci 74:1999-2008.
40. Sivitz WI, Walsh SA, Morgan DA, Thomas MJ, Haynes WG (1997). Effects of leptin on insulin sensitivity in normal rats. Endocrinology 138:3395-3401.
41. Sivitz WI, Wayson SM, Bayless ML, Larson LF, Sinkey C, Robert S (2003). Leptin and body fat in type 2 diabetes and monodrug therapy. J Clin Endocrinol Metab 88:1543-1553.
42. Schuld A, Kraus T, Haack M, Hinza-Selch D, Kühn M, Pollmächer T (2000). Plasma levels of cytokines and soluble cytokine receptors during treatment with olanzapine. Schizophr Res 43:164-166.
43. Vestri HS, Maianu L, Moellering DR, Garvey WT (2006). Atypical antipsychotic drugs directly impair insulin action in adipocytes: effects on glucose transport, lipogenesis, and antilipolysis. Neuropsychopharmacology (Epub ahead of print) (in press).
44. Visser M, Bouter L, McQuillan G, Wener M, Harris T (1999). Elevated C-reactive protein levels in overweight and obese adults. JAMA 282:2131-2135.
45. Wannamethee SG, Tchernova J, Whincup P, Lowe GD, Kelly A, Rumley A, et al. (2006). Plasma leptin: associations with metabolic, inflammatory and haemostatic risk factors for cardiovascular disease. Atherosclerosis (Epub ahead of print) (in press).
46. Yudkin JS, Stehouwer CDA, Emeis JJ, Coppack SW (1999). C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction. Arterioscler Thromb Vasc Biol 19:972-978.
47. Zhang XY, Zhou DF, Cao LY, Wu GY (2005). Cortisol and cytokines in chronic and treatment-resistant patients with schizophrenia: association with psychopathology and response to antipsychotics. Neuropsychopharmacology 30:1532-1538.
48. Zimmet P, Magliano D, Matsuwa Y, Alberti G, Shaw J (2005). The metabolic syndrome: a global public health problem and a new definition. J Atheroscler Thromb 12:295-300.
49. Zornberg GL, Jick H (2000). Antipsychotic drug use and risk of first-time idiopathic venous thromboembolism: a case-control study. Lancet 356:1219-1223.